SEC Filing Summary: Pfizer Inc (13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR (Holdings Report) submitted by Pfizer Inc as an institutional investment manager. The report covers the quarter ended March 31, 2026, and was signed on May 12, 2026, by Madelyn D. Purcell, Assistant General Counsel.
Key Financial Metrics
As a 13F filing, this document reports investment holdings rather than the operating financial performance of Pfizer Inc. Key metrics from this specific filing include:
- Total Value of Reported Holdings: $238,775,816
- Total Number of Holdings Entries: 21
- Other Included Managers: 0
Note: This filing does not contain data on Pfizer Inc's revenue, profit, cash flow, margins, debt, or liquidity. Those metrics are found in the company's 10-Q or 10-K filings.
Material Changes
The filing text does not provide comparative data for the prior period (December 31, 2025) to determine material changes in holdings value or composition. The report is not marked as an amendment or restatement.
Guidance, Outlook, and Risks
This document is a regulatory disclosure of equity holdings and does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding Pfizer Inc's business operations.
Investor Verification Checklist
- Verify the total value of Pfizer Inc's external investment portfolio ($238.8M) against the company's cash and marketable securities reported in its 10-Q for Q1 2026.
- Confirm the specific 21 securities held by reviewing the full Schedule 13F-HR (not included in this summary text).
- Check for any subsequent amendments to this filing if the portfolio value fluctuates significantly before the next reporting deadline.